Trending NewsTrending NewsNYSE:JNJ Johnson & Johnson (JNJ) Stock Price, News & Analysis $274.75 +3.71 (+1.37%) As of 01:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Johnson & Johnson Stock (NYSE:JNJ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Johnson & Johnson alerts:Sign Up Key Stats Today's Range$274.23▼$278.0550-Day Range$248.90▼$278.6652-Week Range$185.12▼$281.07Volume2.79 million shsAverage Volume7.94 million shsMarket Capitalization$661.41 billionP/E Ratio41.60Dividend Yield1.95%Price Target$275.92Consensus RatingModerate Buy Company Overview Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide. Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions. MedTech provides medical devices and technologies used in surgery, orthopaedics, cardiovascular care, vision care and other healthcare settings. The company’s portfolio includes prescription medicines and medical-device brands such as DARZALEX, STELARA, ERLEADA, ETHICON, DePuy Synthes, Biosense Webster and Cerenovus. In 2023, Johnson & Johnson completed the separation of its consumer-health business, which now operates as Kenvue. Joaquin Duato serves as Johnson & Johnson’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Johnson & Johnson Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreJNJ MarketRank™: 3.70986460348 of 5 starsJohnson & Johnson scored higher than 74% of companies evaluated by MarketBeat, and ranked 134th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingJohnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 17 buy ratings, 8 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Johnson & Johnson is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageJohnson & Johnson has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Johnson & Johnson's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth3.87% Earnings GrowthEarnings for Johnson & Johnson are expected to grow by 3.87% in the coming year, from $11.12 to $11.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Johnson & Johnson is 41.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.16.Price to Earnings Ratio vs. SectorThe P/E ratio of Johnson & Johnson is 41.69, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 37.10.Price to Earnings Growth RatioJohnson & Johnson has a PEG Ratio of 2.61. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJohnson & Johnson has a P/B Ratio of 8.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.70% of the float of Johnson & Johnson has been sold short.Short Interest Ratio / Days to CoverJohnson & Johnson has a short interest ratio ("days to cover") of 1.97, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Johnson & Johnson has recently decreased by 24.03%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldJohnson & Johnson pays a meaningful dividend of 2.03%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthJohnson & Johnson has been increasing its dividend for 64 years.Dividend CoverageThe dividend payout ratio of Johnson & Johnson is 81.21%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 46.41% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.Read more about Johnson & Johnson's dividend. News and Social Media3.5 / 5News Sentiment0.53 News SentimentJohnson & Johnson has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 82 news articles for Johnson & Johnson this week, compared to 10 articles on an average week.Search Interest107 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows65 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 97% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,271,766.00 in company stock.Percentage Held by Insiders0.16% of the stock of Johnson & Johnson is held by insiders.Percentage Held by Institutions69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Johnson & Johnson's insider trading history. Receive JNJ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JNJ Stock News HeadlinesJohnson & Johnson : Record 26 Abstracts at TCT 2026 Adds to More than 20 Years of Data Demonstrating the Safety, Efficacy and Cost Effectiveness of Impella Heart Pumps25 minutes ago | marketscreener.comMMerck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher2 hours ago | 247wallst.comThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 29 at 1:00 AM | Behind the Markets (Ad)Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher2 hours ago | 247wallst.com5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps (JNJ)Teradyne, Grail, Kratos Defense, FormFactor and Fabrinet have pulled back despite strong growth, setting up potential entry points in robotics, quantum and AI.October 26 at 1:15 PM | marketbeat.comWhat a Mixed Midterm Result Could Mean for These 2 Health Care ETFs (JNJ)Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.October 19, 2026 | marketbeat.comMarketBeat Week in Review – 10/12 - 10/16 (JNJ)Tech stocks fell on inflation fears and AI infrastructure concerns while the Dow rose, as MarketBeat analysts review earnings outlooks, sector rotation, and stock picks from the week's top stories.October 17, 2026 | marketbeat.comSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJohnson & Johnson posted Q3 revenue growth of 5.9% to $25.4 billion, raised guidance, and gained analyst support as its OTTAVA surgical system and talc settlement shape its long-term outlook.October 13, 2026 | marketbeat.comSee More Headlines JNJ Stock Analysis - Frequently Asked Questions How have JNJ shares performed this year? Johnson & Johnson's stock was trading at $207.07 at the beginning of the year. Since then, JNJ shares have increased by 32.9% and is now trading at $275.1340. How were Johnson & Johnson's earnings last quarter? Johnson & Johnson (NYSE:JNJ) released its earnings results on Tuesday, October, 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm's quarterly revenue was up 5.9% on a year-over-year basis. Read the conference call transcript. Does Johnson & Johnson have any subsidiaries? Johnson & Johnson subsidiaries include these companies: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and others. Who are Johnson & Johnson's major shareholders? Johnson & Johnson's top institutional investors include Ninety One UK Ltd (0.27%), Sumitomo Mitsui Trust Group Inc. (0.23%), Assenagon Asset Management S.A. (0.12%) and Robeco Institutional Asset Management B.V. (0.08%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Kathryn E Wengel, Timothy Schmid, Vanessa Broadhurst, Robert J Decker, Elizabeth Forminard and Mark A Weinberger. View institutional ownership trends. How do I buy shares of Johnson & Johnson? Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Johnson & Johnson own? Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include NVIDIA (NVDA), Pfizer (PFE), JPMorgan Chase & Co. (JPM), AbbVie (ABBV), Walmart (WMT), Procter & Gamble (PG) and AT&T (T). Company Calendar Record date for 9/8 Dividend8/25/2026Ex-Dividend for 9/8 Dividend8/25/2026Dividend Payable9/08/2026Last Earnings10/13/2026Today10/29/2026Record date for 12/8 Dividend11/24/2026Ex-Dividend for 12/8 Dividend11/24/2026Dividend Payable12/08/2026Investor update12/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 9 days, JNJ's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:JNJ CIK200406 Webwww.jnj.com Phone(732) 524-0400Fax732-214-0332Employees138,200Year Founded1886Price Target and Rating Average Price Target for Johnson & Johnson$275.92 High Price Target$320.00 Low Price Target$210.00 Potential Upside/Downside+0.3%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$6.60 Trailing P/E Ratio41.67 Forward P/E Ratio24.73 P/E Growth2.61Net Income$26.80 billion Net Margins16.20% Pretax Margin17.86% Return on Equity31.64% Return on Assets13.04% Debt Debt-to-Equity Ratio0.44 Current Ratio1.02 Quick Ratio0.74 Sales & Book Value Annual Sales$99.34 billion Price / Sales6.66 Cash Flow$14.72 per share Price / Cash Flow18.68 Book Value$33.85 per share Price / Book8.12Miscellaneous Outstanding Shares2,407,310,000Free Float2,403,458,000Market Cap$662.03 billion OptionableOptionable Beta0.21 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NYSE:JNJ) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Johnson & Johnson Please log in to your account or sign up in order to add this asset to your watchlist. Share Johnson & Johnson With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
